Monopar Therapeutics (NASDAQ:MNPR) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a report issued on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $70.00 target price on the stock. HC Wainwright also issued estimates for Monopar Therapeutics’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($1.78) EPS, Q1 2026 earnings at ($0.58) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.35) EPS.

Other equities research analysts have also recently issued research reports about the company. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Finally, Cantor Fitzgerald started coverage on shares of Monopar Therapeutics in a report on Monday, July 7th. They issued an “overweight” rating and a $74.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Monopar Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $66.00.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $36.06 on Tuesday. Monopar Therapeutics has a one year low of $2.25 and a one year high of $54.30. The stock has a market capitalization of $222.49 million, a PE ratio of -10.83 and a beta of 1.05. The company’s 50-day moving average price is $37.87 and its two-hundred day moving average price is $37.04.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12. On average, analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In other Monopar Therapeutics news, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the chief executive officer directly owned 73,472 shares of the company’s stock, valued at $2,938,880. This represents a 18.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $356,160.00. Following the completion of the transaction, the director directly owned 11,486 shares in the company, valued at approximately $459,440. This represents a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock valued at $1,700,160 over the last ninety days. 20.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

A number of large investors have recently made changes to their positions in MNPR. JPMorgan Chase & Co. bought a new position in shares of Monopar Therapeutics during the fourth quarter worth approximately $45,000. Geode Capital Management LLC increased its position in Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after buying an additional 24,530 shares during the period. RA Capital Management L.P. bought a new position in Monopar Therapeutics during the 4th quarter worth $11,247,000. Janus Henderson Group PLC bought a new position in Monopar Therapeutics during the fourth quarter worth about $23,435,000. Finally, Point72 Asset Management L.P. bought a new position in Monopar Therapeutics during the fourth quarter worth about $3,694,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.